Biotherapeutic powerhouse Arcutis Biotherapeutics, Inc., a California-based biopharmaceutical firm, has set its sights on revolutionizing dermatological treatments. With a primary focus on developing and commercializing novel therapies for dermatological diseases, it has created a portfolio of treatments that includes ARQ-151 - a topical cream for plaque psoriasis and atopic dermatitis that has already completed Phase III clinical trials. In addition, the company has several other exciting candidates in its pipeline, including ARQ-154, a foam form of its roflumilast therapy for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective janus kinase type 1 inhibitor tackling hand eczema and vitiligo; and ARQ-255, an ivarmacitinib-based solution for alopecia areata. Notable among these is its CD200R fusion protein, ARQ-234, with which the firm hopes to revolutionize the treatment of moderate-to-severe atopic dermatitis. Established in 2016 under the name Arcutis, Inc., the company rebranded as Arcutis Biotherapeutics, Inc. in October of last year, and is headquartered in the beautiful city of Westlake Village.
Arcutis Biotherapeutics's ticker is ARQT
The company's shares trade on the NASDAQ stock exchange
They are based in Westlake Village, California
There are 51-200 employees working at Arcutis Biotherapeutics
It is arcutis.com
Arcutis Biotherapeutics is in the Healthcare sector
Arcutis Biotherapeutics is in the Biotechnology industry
The following five companies are Arcutis Biotherapeutics's industry peers: